Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients

Table 1 Baseline clinical characteristics of the patients with acute or chronic graft-vs-host disease treated with ruxolitinib

Parameter	aGVHD, n = 10	cGVHD, n = 28
Age in yr, median (range)	35 (19–55)	30 (14–55)
Sex, n (%)
Female	3 (30.0)	14 (50.0)
Male	7 (70.0)	14 (50.0)
Disease, n (%)
AML	5 (50.0)	11 (39.3)
ALL	2 (20.0)	8 (28.6)
CML	0 (0)	6 (21.4)
MDS	2 (20.0)	3 (10.7)
CMML	1 (10.0)	0 (0)
Donor type, n (%)
Matched related	8 (80.0)	15 (53.6)
Partially mismatched related	2 (20.0)	8 (28.6)
Unrelated	0 (0)	5 (17.9)
Types of transplantation, n (%)
PBSC	6 (60.0)	22 (78.6)
BM-HSC	2 (20.0)	1 (3.6)
PBSC + BM-HSC	2 (20.0)	5 (17.9)
Median number of infused nucleated cells as /kg	11.1 × 108	15.62 × 106
Median number of infused CD34+ cells as /kg	5.99 × 106	6.05 × 106
aGVHD of grade 3 or higher, n (%)	9 (90.0)	-
Moderate or severe cGVHD, n (%)	-	24 (85.7)
Multiple organ involvement, n (%)	3 (30.0)	22 (78.6)
Median number of immunosuppressive agents1	2	2
aGVHD stage 3–4 or cGVHD NIH 2–3, n (%)
Skin	5 (50.0)	19 (67.9)
Digestive tract	3 (30.0)	6 (21.4)
Liver	2 (20.0)	4 (14.3)
Eyes	-	12 (42.9)
Oral cavity	-	11 (39.3)
Lungs	-	6 (21.4)
Fascia	-	8 (28.6)

¹Before initiation of ruxolitinib therapy. aGVHD: Acute graft-vs-host disease; ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; BM-HSC: Bone marrow hematopoietic stem cell; cGVHD: Chronic graft-vs-host disease; CML: Chronic myeloid leukemia; CMML: Chronic myelomonocytic leukemia; MDS: Myelodysplastic syndrome; PBSC: Peripheral blood stem cell; NIH: National Institutes of Health.